ENTA
Enanta Pharmaceuticals Inc
NASDAQ: ENTA · HEALTHCARE · BIOTECHNOLOGY
$13.87
+1.17% today
Updated 2026-04-29
Market cap
$386.25M
P/E ratio
—
P/S ratio
5.77x
EPS (TTM)
$-3.21
Dividend yield
—
52W range
$5 – $17
Volume
0.2M
Enanta Pharmaceuticals Inc (ENTA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.18M | $24.02M | $22.62M | $10.65M | $20.18M | $76.67M | $35.81M | $52.65M | $29.22M | $71.42M | $7.09M | $-70.00M | $-84.78M | $-103.15M | $-78.76M | $-19.27M |
| Capital expenditures | $37000.00 | $445000.00 | $252000.00 | $606000.00 | $1.03M | $2.34M | $4.74M | $2.51M | $2.98M | $5.42M | $1.45M | $750000.00 | $2.13M | $9.06M | $17.95M | $12.90M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $259000.00 | $225000.00 | $424000.00 | $1.06M | $2.68M | $5.84M | $9.35M | $13.07M | $15.85M | $19.23M | $19.57M | $20.99M | $26.97M | $28.22M | $26.80M | $18.57M |
| Free cash flow | $-10.21M | $23.57M | $22.37M | $10.05M | $19.15M | $74.34M | $31.07M | $50.15M | $26.24M | $66.00M | $5.64M | $-70.75M | $-86.91M | $-112.21M | $-96.71M | $-32.17M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.66M | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-1.65M | $21.84M | $-8.97M | $-5.15M | $49.10M | $-1.77M | — | $35.90M | $-29.93M | $-9.85M | — | — | — |